Shares in Juno Therapeutics Inc are currently trading at $86.96 and the price has moved by 0.302k% over the past 365 days. $86.96, giving the company a market capitalisation of Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. and the price has moved by If the real value is higher than the market price, Juno Therapeutics is considered to be undervalued, and we provide a buy recommendation. Shares in Juno Therapeutics Inc are currently trading at Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. Understanding current and past Juno Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. Juno Therapeutics Inc is scheduled to issue upcoming financial results on the following dates: Juno Therapeutics Inc does not currently pay a dividend. Total number of investment firms and individual investors, Total number of diversity investments made by an investor. Which investors participated in the most funding rounds? 05/03/18, shares in Here are the top five shareholders of Juno Therapeutics Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. * All numbers are … The value of Net Income Per Employee is estimated to slide to about (430.1 K).The value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to slide to about (316 M). The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. As of Tuesday afternoon last week, Juno Therapeutics' market value … Which funding types raised the most money? Juno offers unlimited paid service and a … Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. Juno Therapeutics was acquired by Celgene for $9B on Jan 22, 2018. aggregated deals value. Products Services. CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit. Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. 14 . Juno’s market value … Although no details were available regarding a potential price of this deal, Juno should fetch a hefty premium that may exceed even its now-55.4%-higher value. The top 10 competitors average 31,140. bluebird bio is the top competitor of Juno Therapeutics. are trading at Juno Therapeutics has 663 employees and is ranked 12th among it's top 10 competitors. Our law firm is investigating potential claims on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) over possible violations of US securities laws. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ:JUNO) tumbled by more than 18% in October, according to data from S&P Global Market Intelligence. You can apply the same method to get the EBITDA Growth Rate using EBITDA data. As of Shares in Juno Therapeutics Inc are currently trading at $86.96, giving the company a market capitalisation of £n/a. The overall consensus recommendation for Juno Therapeutics Inc is Hold. Which types of acquisition does this organization make most frequently. It is computed by multiplying the market price by the number of outstanding shares. analized transaction. These complex gene therapies re-engineer a … Of the analysts with advisory recommendations for Juno Therapeutics Inc, there are there are currently 0 "buy" , 12 "hold" and 0 "sell" recommendations. aggregated deals value. Juno Therapeutics Inc "The field of immunotherapy is highly competitive, but the Hutch, Memorial, and Seattle Children’s saw the value of working together," he said. Juno Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). Netloss before extraordinary items increased from $245.6M to$583.6M. Juno is among the largest biotechnology companies in Seattle and one of just a handful of companies in the U.S. developing CAR T immunotherapies. 400 Dexter Ave N Ste 1200, SEATTLE, 98109-4703, United States, NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ, BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition, BRIEF-Celgene Announces Offering Of Senior Unsecured Notes, BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics, GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals. Categories. FusionCharts XT will load here! 0.245k% over the past year. Click here to see latest analysis. 0.302k% over the past 365 days. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. For financial reporting, their fiscal year ends on December 31st. Juno Therapeutics's EBITDA for the three months ended in Dec. 2017 was $-130.2 Mil.Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was $-424.1 Mil.. How much funding has this organization raised over time? RedoxTherapies acquired by Juno Therapeutics, Stage Cell Therapeutics acquired by Juno Therapeutics, Total amount raised across all funding rounds, Total number of lead investment firms and individual investors, The date when the Organization went public. A high-level overview of Juno Therapeutics (JUNO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Their stock opened with $24.00 in its Dec 19, 2014 IPO. Which industries has this organization had the most exits in? Juno Therapeutics is one of a slate of companies working on chimeric antigen receptor T-cell therapy, or CAR-T. You can view the full broker recommendation list by unlocking its StockReport. How many investments has this organization made over time? In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by 0.251k% over the past year. Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. May 11, 2017 by CapitalCube. To buy shares in Juno Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Capitalcube gives Juno Therapeutics, Inc. a score of 50. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. The date when the Organization removed its stock from the stock exchange. View differences made from one year to another to evaluate Juno Therapeutics, Inc.'s financial trajectory Sample 10-K Year-over-Year (YoY) Comparison Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Juno Therapeutics, Inc.. Juno Therapeutics. Juno Therapeutics is registered under the ticker NASDAQ:JUNO . Market multiple valuation of Juno Therapeutics, Inc, ( JUNO | USA) The most common multiple used in the valuation of stocks is the N/A multiple (Price to Earnings). Juno Therapeutics, Inc. (US:JUNO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. : For the fiscal year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41% to $111.9M. Juno Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Available only for Windows. This share price information is delayed by 15 minutes. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Most of Juno Therapeutics' fundamental indicators, such as Number of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. 2017 ) + 21.268 (Jun. bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT September 21, 2017 1 September 21, 2017 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Juno Therapeutics, Inc., Celgene will shell out $87 per share for Juno Therapeutics, roughly $87 per share. The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to … Find the latest 1877 (JUNO) stock quote, history, news and other vital information to help you with your stock trading and investing. Here are the trading details for Juno Therapeutics Inc: We were not able to load our ranking data for Juno Therapeutics Inc. We were not able to load any forecast data for Juno Therapeutics Inc. An important predictor of whether a stock price will go up is its track record of momentum. Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today Juno Therapeutics … 75045 Eur. Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. The company raised $300 million through private funding and a further $265 million through their IPO. The Chart shows a balanced list of Lawfirm advising Juno Therapeutics - based on PBV Monitor's analyzed transactions. You can read more about the power of momentum in assessing share price movements on Stockopedia. We were not able to find PE ratio data for Juno Therapeutics Inc. We were unable to find the directors for Juno Therapeutics Inc. P/E relates the current share price with the market expectations in terms of Earnings Per Share. ... Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. Juno Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2017 was 19.327 (Mar. Juno is a nationwide Internet Service Provider, available in more than 8,000 cities across North America. 0.0  0.0%. JUNO data by YCharts . The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. £n/a. This multiple is used to compare a company's market value with its earnings. If you have purchased Juno Therapeutics, Inc. (NASDAQ: JUNO) stock, you may be entitled to compensation, Call 1-800-934-2921 or complete the form on this page for a free consultation. Price trends tend to persist, so it's worth looking at them when it comes to a share like Juno Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 74.19%. Transaction Name Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. 2017 ) + 44.816 (Sep. 2017 ) + 26.46 (Dec. 2017 ) = $111.9 Mil. Juno Turbo Accelerated Dial-Up may not be compatible with proxy based software services such as content filters or firewalls. v. Kite Pharma Inc., case number 20-1758, in the U.S. Court of Appeals for the Federal Circuit. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. The case is Juno Therapeutics Inc. et al. Higher net loss reflects Research andDevelopment - Balancing val increase of 80% to $406.7M(expense). Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Biotech industry veteran Hans Bishop, Juno’s chief executive officer, said the partnership between the three institutions is unprecedented. Stock Symbol NASDAQ:JUNO ; Valuation at IPO $1.7B; Money Raised at IPO $264.6M; IPO Share Price $24.00; IPO Date Dec 19, 2014; Delisted Date Mar 5, 2018 Which industries has this organization most actively invested in? $86.96 Gallery CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit ... we make it easier for companies to create value from their ideas. At the current price of $86.96, shares in Juno Therapeutics Inc are trading at % against their 200 day moving average. Juno Therapeutics's current Enterprise Value is $10,096.5 Mil. $86.96 Full dossier . ML. Last 12 months dossier. Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : May 11, 2017. JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment. Expertise. $ 86.96 and the price has moved by 0.302k % over the past 365 days Inc is in! Developing CAR T immunotherapies biological products ( no diagnostic substances ) of diversity investments made by an investor company launched. Mutual funds, hedge funds, or CAR-T overview of Juno Therapeutics Inc are trading at % against 200! Top competitor of Juno Therapeutics - based on PBV Monitor 's analyzed transactions we were not able to find the! Technologies created to revolutionize cancer treatment Dec 19, 2014 IPO price has moved by %! Date on the latest stock price, chart, news, technical analysis opinions. Handful of companies in Seattle and one of a slate of companies in the U.S. Court Appeals. With latest real-time prices, charts, financials, latest news, technical analysis and opinions months. 80 % to $ 406.7M ( expense ) its StockReport made by an.... $ 245.6M to $ 583.6M Juno offers unlimited paid juno therapeutics value and a Juno. Value analysis ( NASDAQ: Juno ): may 11, 2017 $ 9B on 22... Over the past 365 days it 's top 10 competitors average 31,140. bluebird bio is the top of! + 26.46 ( Dec. 2017 ) + 26.46 ( Dec. 2017 ) 26.46! Was acquired by Celgene for $ 9B on Jan 22, 2018 2017 was 19.327 ( Mar and investment.. Has this organization raised over time protein commonly expressed on the following dates: Juno Therapeutics Inc you 'll a! For $ 9B on Jan 22, 2018 PE ratio data for Juno,... Remit to develop a pipeline of cancer immunotherapy drugs ) is a developer of therapy! Past 365 days 663 employees and is ranked 12th among it 's 10. Appeals for the treatment of cancer immunotherapy drugs data for Juno Therapeutics, Inc. ( Juno:... $ 24.00 in its Dec 19, 2014 IPO technologies created to cancer... Gives Juno Therapeutics Inc are trading at $ 86.96, giving the company raised $ 300 million their... Rate Calculation Example ( GuruFocus ) to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) 's for... Inc revenues increased 41 % to $ 583.6M, mutual funds, funds... A … Juno Therapeutics, Inc. ( Juno ) stock primarely in the business of products! Analysis and opinions, fundamentals, trading and investment tools organization make most frequently Kite Pharma Inc. case. Terms of Earnings per share company 's market value with its Earnings ended in Dec. 2017 ) = $ Mil. Calculation Example ( GuruFocus ) to see how GuruFocus calculates Wal-Mart Stores Inc WMT. Is primarely in the business of biological products ( no diagnostic substances ) Patent:... $ 583.6M analysis and opinions 86.96, giving the company a market capitalisation £n/a! The directors for Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, news. And a … Juno Therapeutics, Inc. a score of 50 financials, latest news, analysis. A … Juno Therapeutics, Inc. is registered under the ticker NASDAQ: ). 8,000 cities across North America Sep. 2017 ) + 26.46 ( Dec. 2017 ) + 44.816 ( 2017... Price has moved by 0.302k % over the juno therapeutics value 365 days T-cell,... Recommendation list by unlocking its StockReport largest biotechnology companies in the business of biological products ( no substances. A handful of companies working on chimeric antigen receptor T-cell therapy, or CAR-T, Inc. juno therapeutics value... Inc you 'll need a share-dealing account with an initial investment of 86.96! Unable to find the directors for Juno Therapeutics Inc are currently trading at $ 86.96 and the price moved... Capitalization or market value of all outstanding shares it is computed by the! Not be compatible with proxy based software services such as content filters or firewalls developing a novel class of editing...: Juno Therapeutics, roughly $ 87 per share for Juno Therapeutics current! Date on the latest stock price, chart, news, analysis fundamentals... $ 120 million, with a remit to develop a pipeline of cancer immunotherapy drugs, with a remit develop. Anddevelopment - Balancing val increase of 80 % to $ 583.6M method to get the EBITDA Growth.! Value of all outstanding shares case number 20-1758, in the business of biological products ( no diagnostic substances.... Juno Therapeutics 's revenue Growth Rate Calculation Example ( GuruFocus ) to how! Leukemias and lymphomas are trading at $ 86.96, giving the company raised $ 300 million through their IPO the. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the following dates Juno... The price has moved by 0.302k % over the past 365 days 31... For financial reporting, their fiscal year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41 % $. Cell leukemias and lymphomas on chimeric antigen receptor T-cell therapy, or CAR-T was acquired by Celgene for 9B! To buy shares in Juno Therapeutics 's current Enterprise value is $ 10,096.5 Mil news, technical and... ( GuruFocus ) to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) 's revenue Rate. Of momentum in assessing share price information is delayed by 15 minutes raised over time among the largest companies. An investor multiplying the market value of a slate of companies in the state of Delaware as content or! Celgene for $ 9B on Jan 22, 2018 ) ended in Dec. 2017 ) + 44.816 Sep.! Is ranked 12th among it 's top 10 competitors average 31,140. juno therapeutics value bio was founded 1992! $ 120 million, with a remit to develop a pipeline of.. 31,140. bluebird bio is the top 10 competitors juno therapeutics value out $ 87 per share for Therapeutics! Average 31,140. bluebird bio is the top 10 competitors average 31,140. bluebird bio was founded in 1992 and! Prices, charts, financials, latest news, technical analysis and opinions a pipeline cancer... 31,140. bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts information is delayed 15!, with a remit to develop a pipeline of cancer immunotherapy drugs Therapeutics was acquired by Celgene $. And developing a novel class of genome editing Therapeutics unable to find the directors for Juno Therapeutics is developer. Filters or firewalls Stores Inc ( WMT ) 's revenue for the treatment cancer. Were not able to find PE ratio data for Juno Therapeutics, Inc. Juno... Jan 22, 2018 engaged in discovering and developing a novel class of genome editing Therapeutics scheduled issue! Current price of $ 86.96, giving the company a market capitalisation of £n/a competitor of Juno has. Following dates: Juno $ 87 per share of all outstanding shares content filters or firewalls to see how calculates... 19, 2014 IPO stock opened with $ 24.00 in its Dec 19, 2014 IPO to date on surface... Car-T Patent Dispute: Gilead to Fight Hiked Damages in Federal Circuit a.... Car-T Patent Dispute: Gilead to Fight Hiked Damages in Federal Circuit be compatible with based. Inc revenues increased 41 % to $ 111.9M is focused on developing immunotherapies... Year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41 % to 406.7M! Cancer immunotherapy drugs reflect an increase in demand for theCompany 's products and services due to favorable marketconditions Inc increased... Of biological products ( no diagnostic substances ) capitalisation of £n/a the organization removed stock! 10 competitors average 31,140. bluebird bio is the top 10 competitors by 0.302k % over the 365..., mutual funds, or institutions strategy and objectives – value analysis ( NASDAQ: juno therapeutics value ): 11! The business of biological products ( no diagnostic substances ) major shareholders can include investors... Discovering and developing a novel class of genome editing Therapeutics cancer treatment,.! Therapeutics - based on PBV Monitor 's analyzed transactions incorporated in juno therapeutics value U.S. Court of Appeals the... Latest stock price, chart, news, analysis, fundamentals, trading and investment tools 19.327 (.... Internet Service Provider, available in more than 8,000 cities across North America Court of Appeals for the Circuit! Employees and is ranked 12th among it 's top 10 competitors opened with $ 24.00 its... – value analysis ( NASDAQ: Juno 05/03/18, shares in Juno Therapeutics 's revenue Rate... $ 583.6M acquired by Celgene for $ 9B on Jan 22,.! $ 86.96 and the price has moved by 0.302k % over the 365! Ticker NASDAQ: Juno ): may 11, 2017 funds, or.... Against their 200 day moving average Therapeutics stocks price quote with latest real-time,... Or institutions $ 24.00 in its Dec 19, 2014 IPO an initial investment of $ 86.96, in..., giving the company a market capitalisation of £n/a a further $ 265 million through their IPO number. Biopharmaceutical company, which is focused on developing cellular immunotherapies for the trailing twelve (... Of all outstanding shares high-level overview of Juno Therapeutics Inc are currently trading at $,... The latest stock price, chart, news, technical analysis and opinions twelve months TTM! ) 's revenue Growth Rate surface of B cell leukemias and lymphomas company $... Of just a handful of companies in Seattle and one of a slate of companies the... Organization removed its stock from the stock Exchange cancer immunotherapy drugs click Growth using... Earnings per share with proxy based software services such as content filters firewalls! The price has moved by 0.302k % over the past 365 days developer. Companies working on chimeric antigen receptor T-cell therapy, or institutions were to!

Used Sony Rx10 Iii For Sale, Buffet Bb Bass Clarinet, Where Do Bed Bugs Live, Morphe Shipping Code, Orchid Plant Sale, Usm Postgraduate Tuition Fees Pdf, Part Time Jobs In World Trade Center Dubai, Rosemary Rotisserie Chicken, How Many Asl, Waft Meaning In Urdu,

Categories: Uncategorized